These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

589 related items for PubMed ID: 27821627

  • 1. A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.
    Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC.
    J Am Soc Nephrol; 2017 Apr; 28(4):1306-1313. PubMed ID: 27821627
    [Abstract] [Full Text] [Related]

  • 2. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
    Li X, Liu Y, Lv J, Shi S, Liu L, Chen Y, Zhang H.
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121
    [Abstract] [Full Text] [Related]

  • 3. Plasma Galactose-Deficient IgA1 and C3 and CKD Progression in IgA Nephropathy.
    Chen P, Yu G, Zhang X, Xie X, Wang J, Shi S, Liu L, Lv J, Zhang H.
    Clin J Am Soc Nephrol; 2019 Oct 07; 14(10):1458-1465. PubMed ID: 31511226
    [Abstract] [Full Text] [Related]

  • 4. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C, Torres DD, Rossini M, Pesce F, Schena FP.
    Nephrol Dial Transplant; 2009 Dec 07; 24(12):3694-701. PubMed ID: 19628647
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
    Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V, DUPRO steering committee and PROTECT Investigators.
    Lancet; 2023 Dec 02; 402(10417):2077-2090. PubMed ID: 37931634
    [Abstract] [Full Text] [Related]

  • 6. Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits complicated by immunoglobulin A nephropathy in the renal allograft.
    Sawada A, Kawanishi K, Horita S, Koike J, Honda K, Ochi A, Komoda M, Tanaka Y, Unagami K, Okumi M, Shimizu T, Ishida H, Tanabe K, Nagashima Y, Nitta K.
    Nephrology (Carlton); 2016 Jul 02; 21 Suppl 1():48-52. PubMed ID: 26971743
    [Abstract] [Full Text] [Related]

  • 7. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H, Muryan A, Young P, Forrester M, Iotti A, Pereyra H, Lombi F, Seminario O, Alonso M, Iotti R.
    Medicina (B Aires); 2007 Jul 02; 67(5):445-50. PubMed ID: 18051227
    [Abstract] [Full Text] [Related]

  • 8. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
    Liu LJ, Yang YZ, Shi SF, Bao YF, Yang C, Zhu SN, Sui GL, Chen YQ, Lv JC, Zhang H.
    Am J Kidney Dis; 2019 Jul 02; 74(1):15-22. PubMed ID: 30922594
    [Abstract] [Full Text] [Related]

  • 9. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
    Cheng G, Liu D, Margetts P, Liu L, Zhao Z, Liu Z, Tang L, Fang Y, Li H, Guo Y, Chen F, Liu F.
    Nephrology (Carlton); 2015 Feb 02; 20(2):77-84. PubMed ID: 25358874
    [Abstract] [Full Text] [Related]

  • 10. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.
    Li P, Chen YZ, Lin HL, Ni ZH, Zhan YL, Wang R, Yang HT, Fang JA, Wang NS, Li WG, Sun XF, Chen XM.
    Trials; 2017 Apr 11; 18(1):170. PubMed ID: 28395659
    [Abstract] [Full Text] [Related]

  • 11. Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study).
    Shima Y, Nakanishi K, Sako M, Saito-Oba M, Hamasaki Y, Hataya H, Honda M, Kamei K, Ishikura K, Ito S, Kaito H, Tanaka R, Nozu K, Nakamura H, Ohashi Y, Iijima K, Yoshikawa N, Japanese Study Group of Kidney Disease in Children (JSKDC).
    Pediatr Nephrol; 2019 May 11; 34(5):837-846. PubMed ID: 30284023
    [Abstract] [Full Text] [Related]

  • 12. ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study.
    Pozzi C, Del Vecchio L, Casartelli D, Pozzoni P, Andrulli S, Amore A, Peruzzi L, Coppo R, Locatelli F, Adulto e Bambino Study Group, Immunopatologia Renale Study Group of the Italian Society of Nephrology.
    J Nephrol; 2006 May 11; 19(4):508-14. PubMed ID: 17048209
    [Abstract] [Full Text] [Related]

  • 13. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
    Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, Monaghan H, Zhao M, Barbour S, Reich H, Cattran D, Glassock R, Levin A, Wheeler D, Woodward M, Billot L, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Wang HY, Perkovic V, TESTING Study Group.
    JAMA; 2017 Aug 01; 318(5):432-442. PubMed ID: 28763548
    [Abstract] [Full Text] [Related]

  • 14. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
    Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC, HKVIN Study Group.
    Am J Kidney Dis; 2006 May 01; 47(5):751-60. PubMed ID: 16632013
    [Abstract] [Full Text] [Related]

  • 15. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial.
    Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK.
    Am J Kidney Dis; 2008 May 01; 51(5):724-31. PubMed ID: 18436082
    [Abstract] [Full Text] [Related]

  • 16. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial.
    Praga M, Gutiérrez E, González E, Morales E, Hernández E.
    J Am Soc Nephrol; 2003 Jun 01; 14(6):1578-83. PubMed ID: 12761258
    [Abstract] [Full Text] [Related]

  • 17. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
    Eitner F, Ackermann D, Hilgers RD, Floege J.
    J Nephrol; 2008 Jun 01; 21(3):284-9. PubMed ID: 18587715
    [Abstract] [Full Text] [Related]

  • 18. Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.
    Min L, Wang Q, Cao L, Zhou W, Yuan J, Zhang M, Che X, Mou S, Fang W, Gu L, Zhu M, Wang L, Yu Z, Qian J, Ni Z.
    Oncotarget; 2017 Jul 18; 8(29):48375-48384. PubMed ID: 28415636
    [Abstract] [Full Text] [Related]

  • 19. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial.
    Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY.
    Am J Kidney Dis; 2012 Jan 18; 59(1):67-74. PubMed ID: 22019331
    [Abstract] [Full Text] [Related]

  • 20. Immunosuppressive therapy in patients with IgA nephropathy.
    Peters HP, van den Brand JA, Berger SP, Wetzels JF.
    Neth J Med; 2015 Jul 18; 73(6):284-9. PubMed ID: 26228193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.